Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Patent
1995-04-14
2000-01-18
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
4241851, 4241921, 4242781, 4242822, 530402, 530403, A61K 3800, C07K 14705, C07K 1900
Patent
active
060155671
ABSTRACT:
A method of treating a human patient via active immunotherapy comprising administrating an effective amount of extracellular portion of human HER2 receptor to the patient wherein the method provokes a cell-mediated immune response to HER2 receptor in the patient treated therewith.
REFERENCES:
patent: 4761371 (1988-08-01), Bell et al.
patent: 4877611 (1989-10-01), Cantrell
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4963354 (1990-10-01), Shepard
patent: 4968603 (1990-11-01), Slamon
patent: 5030576 (1991-07-01), Dull et al.
patent: 5081228 (1992-01-01), Dower et al.
patent: 5126433 (1992-06-01), Maddon et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5401638 (1995-03-01), Carney et al.
Yamamoto et al Nature 119: 230-234 1986.
Derbin PNAS 83 9129-9133 1986.
Mitchell et Al Cancer Res 48: 5883-5893 1988.
Hoover et al Cancer 55: 1236-1243 1985.
Capon et al Nature 337: 525-531 1989.
Tal et al Cancer Res. 48: 1517-1520 1988.
Zhou et al Cancer Res. 47: 6123-6125 1987.
Bernards et al PNAS 84: 6854-6858 1987.
Ezell,C J. of NIH Research 7: 46-49 1995.
Akiyama et al., "The product of the human c-erbB-2 Gene: a 185-Kilodalton Glycoprotein with tyrosine Kinase Activity" Science 232:1644-1646 (1986).
Bargmann et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein" Nature 319:226-230 (1986).
Bernards et al., "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector" Proc. Natl. Acad. Sci. USA 84:6854-6858 (1987).
Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene" Science 230:1132-1139 (1985).
Drebin et al., "Down-Modulation of an Oncogene Protein Product an Reversion of the Transformed Phenotype by Monoclonal Antobodies" Cell 41(3):695-706 (1985).
Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" Proc. Natl. Acad. Sci. 83:9129-9133 (1986).
Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" Oncogene 2:273-277 (1988).
Drebin et al., "Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo" Oncogene 2(4):387-394 (1988).
Fendly et al., "The Extracellular Domain of HER2
eu Is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer" Journal of Biological Response Modifiers 9:449-455 (1990).
Fendly et al., "Successful Immunization of Rhesus Monkeys with Extracellular Domain of p185.sup.HER2 : A Potential Approach to Human Breast Cancer" Vaccine Research 2(3):129-139 (1993).
Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" Virology 52:456-467 (1973).
Hopp et al., "Prediction of protein antigenic determinants from amino acid sequences" Proc. Natl. Acad. Sci. USA 78(6):3824-3828 (1981).
Hudziak et al., "Amplified Expression of the HER2/ERBB2 Oncogene Induces Resistance to Tumor Necrosis Factor .alpha. in NIH 3T3 Cells" Proc. Natl. Acad. Sci. USA 85:5102-5106 (1988).
Hudziak et al., "Increased expression of the putative growth factor receptor p185.sup.HER2 causes transformation and tumorigenesis of NIH 3T3 cells" Proc. Natl. Acad. Sci. 84:7159-7163 (1987).
Hudziak et al., "p185.sup.HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" Molecular & Cellular Biology 9(3):1165-1172 (1989).
Kane et al., "Formation of recombinant protein inclusion bodies in Escherichia coli" Tibtech 6:95-101 (1988).
Kaufman et al., "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene" J. Mol. Biol. 159:601-621 (1982).
King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" Science 229:974-976 (1985).
Kraus et al., "Overexpression of the EGF receptor-related proto- oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms" EMBO Journal 6(3):605-610 (1987).
Langton et al., "An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2
eu) oncogene" Cancer Research 51:2593-2598 (1991).
Lin et al., "A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells" Oncogene 6:639-643 (1991).
Margalit et al., "Prediction of Immunodominant Helper T Cell Antigenic Sites from the Primary Sequence" J. Immunol. 138(7):2213-2229 (1987).
Masuko et al., "A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product" Jpn J. Cancer Res. 80:10-14 (1989).
Padhy et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas" Cell 28:865-871 (1982).
Plowman et al., "Ligand-specific activation of HER4/p180.sup.erbB4, a fourth member of the epidermal growth factor receptor family" Proc. Natl. Acad. Sci. USA 90:1746-1750 (1993).
Schecter et al., "The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen" Nature 312:513-516 (1984).
Schein, Catherine H., "Production of soluble recombinant proteins in bacteria" Bio/Technology 7:1141-1149 (1989).
Semba et al., "A v-erbB-related protooncogene c-erbB-2, is distinct from the c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma" Proc. Natl. Acad. Sci. USA 82:6497-6501 (1985).
Shepard et al., "P185HER2 Monoclonal Antibody has Anti Proliferative Effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor" J. Cell Biochem. (Abstract D253) p. 42 (1989).
Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene" Science 235:177-182 (1987).
Sliwkowski et al., "Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin" Journal of Biological Chemistry 269(20):14661-14665 (1994).
Van de Vijver et al., "Amplification of the neu (c-erbB-2) Oncogene in Human Mammary Tumors Is Relatively Frequent and Is Often Accompanied by Amplification of the Linked c-erbA Oncogene" Molecular & Cellular Biology 7(5):2019-2023 (1987).
Weber et al., "Medium-scale ligand-affinity purification of two soluble forms of human interleukin-2 receptor" J. Chromatography 431:55-63 (1988).
Yamamoto et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor" Nature 319:230-34 (1986).
Yanisch-Perron et al., "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors" Gene 33:103-119 (1985).
Yarden et al., "Epidermal Growth Factor Induces Rapid, Reversible Aggregation of the Purified Epidermal Growth Factor Receptor" Biochemistry 26:1443-1451 (1987).
Yarden et al., "Growth Factor Receptor Tyrosine Kinases" Ann. Rev. Biochem. 57:443-478 (1988).
Yarden et al., "Molecular Analysis of Signal Transduction by Growth Factors" Biochemistry 27(9):3113-3119 (1988).
Yokota et al., "Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue" Oncogene 2:283-287 (1988).
Zhou et al., "Association of Multiple Copies of the c-erbB-2 Oncogene with Spread of Breast Cancer" Cancer Research 47:6123-6125 (1987).
Basu et al., "Inhibition of Tyrosine Kinase Activity of the Epidermal Growth Factor (EGF) Receptor by a Truncated Receptor Form that Binds to EGF: Role for Interrecptor Interaction in Kinase Regulation" Molecular & Cellular Biology 9(2):671-677 (Feb. 1989).
Disis et al., "Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients with Breast Cancer" Cancer Research 54:16-20 (Jan. 1, 1994).
Drebin et al., "Monoclonal Antibodies Identify a Cell-surface Antigen Associated with an Activated Cellular Oncogene" Nature 312:545-548 (Dec. 6, 1984).
Duan et al., "A Functional Soluble Extracellular Region of the Platelet-d
Hudziak Robert Michael
Shepard H. Michael
Ullrich Axel
Cunningham Thomas M.
Genentech Inc.
Lee Wendy M.
Lubet Martha
LandOfFree
HER2 extracellular domain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HER2 extracellular domain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HER2 extracellular domain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-561296